HIKAL Q2 FY27 CONCALL: MAINTAINS MID-TEENS FY27 REVENUE GROWTH GUIDANCE; TARGETS ~18.5% H2 EBITDA MARGIN, US FDA RE-INSPECTION BY FY27-END & ₹150 CR ANNUAL REVENUE UPSIDE POST-CLEARANCE